Biotech Consultancy Services

biotechconsultancy.net

Headquartered in Singapore, BCS provided specialist advice that focused on technical and commercial management strategies into the agri-biotechnology industry. The founder, Edward Manchester, is now engaged as Regional Director with Biomin Asia, based in Singapore.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY, INDUSTRIAL IMPACT

IMMUNOGEN ANNOUNCES MULTI-TARGET LICENSING AND OPTION DEAL WITH VERTEX

ImmunoGen, Inc. | March 02, 2023

news image

On March 1, 2023, ImmunoGen, Inc., a leading firm specializing in antibody-drug conjugates (ADCs), announced a global, multi-target license and option agreement with Vertex Pharmaceuticals. The deal provides Vertex with the rights to use ImmunoGen's ADC technology to research and discover targeted conditioning agents to be used in gene editing. After each research period, Vertex will have the option to obtain an exclusive worldwide license to research, develop, and commercia...

Read More

ACCESS BIOLOGICALS COMPLETES THE FIRST-EVER COMMERCIALLY AVAILABLE COVID-19 SEROCONVERSION PANEL TO CONFIRM SARS-COV-2 ANTIBODY ASSAYS

PR Newswire | September 07, 2020

news image

Access Biologicals, a market leader in the collection and manufacturing of biologicals products, today announced it has completed the first-ever commercially available COVID-19 seroconversion panel to confirm the presence of anti-SARS-CoV-2 antibodies. Efforts to contain the spread of COVID-19 rely in part on serological tests to identify the presence of anti-SARS-CoV-2 antibodies in people who have had the illness. Until now, however, many of these tests have been developed rapidly and without ...

Read More

INDUSTRIAL IMPACT, MEDICAL

BIOVAXYS AND PROCARE HEALTH EXECUTE US DISTRIBUTION AGREEMENT FOR PAPILOCARE GEL AND ORAL IMMUNOCAPS

BioVaxys Technology Corp. | December 20, 2022

news image

BioVaxys Technology Corp. and Procare Health Iberia, of Barcelona, Spain announced that they have finalized and executed the United States Distribution Agreement for Papilocare® and Oral Immunocaps©. Following the binding Term Sheet executed by the two companies in early October 2022, the Distribution Agreement finalized all remaining aspects of the transaction. Developed by Procare Health, Papilocare® is the world's first and only patented vaginal gel product wit...

Read More

A FUTURE GENE THERAPY COULD BE DELIVERED IN TINY ‘NANOCONTAINERS’

Labiotech.eu | January 28, 2020

news image

A Swiss research group has developed tiny plastic particles that could carry gene therapies to the center of the cell with less risk of getting attacked by the immune system than conventional gene therapies. The majority of gene therapies in use today are delivered to the DNA of target cells using viral vectors. While efficient at their job, viral vectors can risk triggering the immune system to destroy them. This can lead to the therapy becoming ineffective....

Read More
news image

CELL AND GENE THERAPY, INDUSTRIAL IMPACT

IMMUNOGEN ANNOUNCES MULTI-TARGET LICENSING AND OPTION DEAL WITH VERTEX

ImmunoGen, Inc. | March 02, 2023

On March 1, 2023, ImmunoGen, Inc., a leading firm specializing in antibody-drug conjugates (ADCs), announced a global, multi-target license and option agreement with Vertex Pharmaceuticals. The deal provides Vertex with the rights to use ImmunoGen's ADC technology to research and discover targeted conditioning agents to be used in gene editing. After each research period, Vertex will have the option to obtain an exclusive worldwide license to research, develop, and commercia...

Read More
news image

ACCESS BIOLOGICALS COMPLETES THE FIRST-EVER COMMERCIALLY AVAILABLE COVID-19 SEROCONVERSION PANEL TO CONFIRM SARS-COV-2 ANTIBODY ASSAYS

PR Newswire | September 07, 2020

Access Biologicals, a market leader in the collection and manufacturing of biologicals products, today announced it has completed the first-ever commercially available COVID-19 seroconversion panel to confirm the presence of anti-SARS-CoV-2 antibodies. Efforts to contain the spread of COVID-19 rely in part on serological tests to identify the presence of anti-SARS-CoV-2 antibodies in people who have had the illness. Until now, however, many of these tests have been developed rapidly and without ...

Read More
news image

INDUSTRIAL IMPACT, MEDICAL

BIOVAXYS AND PROCARE HEALTH EXECUTE US DISTRIBUTION AGREEMENT FOR PAPILOCARE GEL AND ORAL IMMUNOCAPS

BioVaxys Technology Corp. | December 20, 2022

BioVaxys Technology Corp. and Procare Health Iberia, of Barcelona, Spain announced that they have finalized and executed the United States Distribution Agreement for Papilocare® and Oral Immunocaps©. Following the binding Term Sheet executed by the two companies in early October 2022, the Distribution Agreement finalized all remaining aspects of the transaction. Developed by Procare Health, Papilocare® is the world's first and only patented vaginal gel product wit...

Read More
news image

A FUTURE GENE THERAPY COULD BE DELIVERED IN TINY ‘NANOCONTAINERS’

Labiotech.eu | January 28, 2020

A Swiss research group has developed tiny plastic particles that could carry gene therapies to the center of the cell with less risk of getting attacked by the immune system than conventional gene therapies. The majority of gene therapies in use today are delivered to the DNA of target cells using viral vectors. While efficient at their job, viral vectors can risk triggering the immune system to destroy them. This can lead to the therapy becoming ineffective....

Read More